Patients and medical personnel in Yucatán say shortages of antiretroviral medicines at CAPASITS clinics are affecting adults and minors, with delays that can last days or even weeks. The complaints describe people traveling from municipalities outside Mérida, and in some cases foreign residents, only to be told their medication is unavailable. A local report published in January described similar problems, including repeat visits and added transport costs for patients who depend on public treatment.
What CAPASITS is supposed to provide
For many international readers, CAPASITS is the key piece of context. These are Mexico’s specialized outpatient centers for HIV and sexually transmitted infections. The Yucatán state program says it provides antiretroviral treatment, consultations, rapid testing, PrEP, and PEP, and that people who test positive for HIV are referred to CAPASITS units in Mérida, Ticul, or Valladolid for ongoing care. In other words, the public system is built around continuity. When medication is not available, the problem is not marginal. It cuts into the core function these clinics are supposed to serve.
Why treatment interruptions are serious
A shortage like this matters because HIV treatment is time-sensitive. The World Health Organization says a top priority during service disruptions or stockouts is to prevent interruptions in current HIV treatment. U.S. federal HIV guidelines state that stopping or interrupting antiretroviral therapy can lead to viral rebound, immune decline, and clinical progression. That is why patients and doctors do not treat delayed refills as a paperwork issue or a normal inconvenience. For people living with HIV, a missed supply window can become a direct medical risk.
Why this matters in Yucatán
The latest published Yucatán surveillance report shows the scale of the issue. Through November 15, 2025, the state had registered 13,013 HIV cases since 1983, with 9,231 people recorded as living with HIV and 563 new diagnoses in 2025 alone. The same official program information states that services are intended to cover all 106 municipalities, even though specialized CAPASITS care is concentrated in only three cities. That means any sustained supply problem can ripple well beyond Mérida, hitting patients who already face travel, cost, and access barriers before they even reach the clinic.
What readers should watch next
The next question is straightforward. Will patients begin receiving complete refills on time, or will the shortages continue long enough to turn an urgent complaint into a broader access-to-care crisis? On paper, Yucatán’s HIV program promises ongoing treatment and continuity of service. In practice, the current reports suggest that the promise is under pressure. For readers living in Mexico, including foreigners who rely on local health systems, this story is a reminder that healthcare access is often decided not by policy documents, but by whether the medicine is actually on the shelf when a patient needs it.
